Understanding critical quality attributes for nanocrystals from preparation to delivery

Molecules

Volumn 20, Issue 12, 2015, Pages 22286-22300

  Peltonen, Leena ^a   Strachan, Clare ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bioavailability; Drug nanocrystals; Permeation; Precipitation; Solubility; Stability; Supersaturation

Indexed keywords

DRUG; EXCIPIENT; NANOPARTICLE;

CHEMISTRY; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84954357182     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules201219851     Document Type: Article

References (59)

1. Müller, R.H.; Keck, C.M. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur. J. Pharm. Biopharm. 2012, 80, 1-3.
2. Müller, R.H.; Gohla, S.; Keck, C.M. State of the art of nanocrystals-Special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 2011, 78, 1-9.
3. Sinha, B.; Müller, R.H.; Möschwitzer, J.P. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int. J. Pharm. 2013, 453, 126-141.
4. Peltonen, L.; Hirvonen, J.; Laaksonen, T. Drug Nanocrystals and Nanosuspension in Medicine. In Handbook of Nanobiomedical Research, Fundamentals, Applications and Recent Developments, 1 Materials for Nanomedicine; Torchilin, V., Ed.; World Scientific: Singapore, Singapore, 2014; Volume 3, pp. 169-197.
5. Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18, 113-120.
6. Sarnes, A.; Østergaard, J.; Smedegaard Jensen, S.; Aaltonen, J.; Rantanen, J.; Hirvonen, J.; Peltonen, L. Dissolution study of nanocrystal powders of a poorly soluble drug by UV imaging and channel flow methods. Eur. J. Pharm. Sci. 2013, 50, 511-519.
7. Liu, P.; Rong, X.; Laru, J.; van Veen, B.; Kiesvaara, J.; Hirvonen, J.; Laaksonen, T.; Peltonen, L. Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling. Int. J. Pharm. 2011, 411, 215-222.
8. Ghosh, I.; Bose, S.; Vippagunta, R.; Harmon, F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int. J. Pharm. 2011, 409, 260-268.
9. Tuomela, A.; Liu, P.; Puranen, J.; Rönkkö, S.; Laaksonen, T.; Kalesnykas, G.; Oksala, O.; Ilkka, J.; Laru, J.; Peltonen, L. Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo. Int. J. Pharm. 2014, 467, 34-41.
10. Azad, M.; Afolabi, A.; Bhakay, A.; Leonardi, J.; Davé, R.; Bilgili, E. Enhanced physical stabilization of fenofibrate nanosuspensions via wet co-milling with a superdisintegrant and an adsorbing polymer. Eur. J. Pharm. Biopharm. 2015, 94, 372-385.
11. El-Setouhy, D.A.; Basalious, E.B.; Abdelmalak, N.S. Bioenhanced sublingual tablet of drug with limited permeability using novel surfactant binder and microencapsulated polysorbate: In vitro /in vivo evaluation. Eur. J. Pharm. Biopharm. 2015, 94, 386-392.
12. Guo, Y.; Luo, J.; Tan, S.; Otieno, B.O.; Zhang, Z. The applications of vitamin E TPGS in drug delivery. Eur. J. Pharm. Sci. 2013, 49, 175-186.
13. Lai, F.; Pini, E.; Corrias, F.; Perricci, J.; Manconi, M.; Fadda, A.M.; Sinico, C. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying. Int. J. Pharm. 2014, 467, 27-33.
14. Liu, P.; De Wulf, O.; Laru, J.; Heikkilä, T.; van Veen, B.; Kiesvaara, J.; Hirvonen, J.; Peltonen, L.; Laaksonen, T. Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions. AAPS PharmSciTech 2013, 14, 748-756.
15. Sarnes, A.; Kovalainen, M.; Häkkinen, M.R.; Laaksonen, T; Laru, J.; Kiesvaara, J.; Ilkka, J.; Oksala, O.; Rönkkö, S.; Järvinen, K.; et al. Nanocrystal-based per-oral itraconazole delivery: Superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption. J. Control. Release 2014, 180, 109-116.
16. Surwase, S.A.; Boetker, J.P; Saville, D.; Boyd, B.J.; Gordon, K.C.; Peltonen, L.; Strachan, C.J. Indomethacin: New polymorphs of an old drug. Mol. Pharm. 2013, 10, 4472-4480.
17. Valo, H.K.; Laaksonen, PH.; Peltonen, L.J.; Linder, M.B.; Hirvonen, J.T.; Laaksonen, T.J. Multifunctional hydrophobin: toward functional coatings for drug nanoparticles. ACS Nano 2010, 4, 1750-1758.
18. Valo, H; Kovalainen, M.; Laaksonen, P.; Häkkinen, M.; Auriola, S.; Peltonen, L.; Linder, M.; Järvinen, K.; Hirvonen, J.; Laaksonen, T. Immobilization of protein-coated drug nanoparticles in nanofibrillar cellulose matrices-Enhanced stability and release. J. Control. Release 2011, 156, 390-397.
19. Valo, H; Arola, S.; Laaksonen, P.; Torkkeli, M.; Peltonen, L.; Linder, M.B.; Serimaa, R.; Kuga, S.; Hirvonen, J.; Laaksonen, T. Drug release from nanoparticles embedded in four different nanofibrillar cellulose aerogels. Eur. J. Pharm. Sci. 2013, 50, 69-77.
20. Heinz, A.; Strachan, C.J.; Gordon, K.C.; Rades, T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J. Pharm. Pharmacol. 2007, 61, 971-988.
21. Darville, N.; van Heerden, M.; Vynckier, A.; de Meulder, M.; Sterkens, P.; Annaert, P.; van den Mooter, G. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. J. Pharm. Sci. 2014, 103, 2072-2087.
22. Strachan, C.J.; Rades, T.; Gordon, K.C.; Rantanen, J. Raman spectroscopy for quantitative analysis of pharmaceutical solids. J. Pharm. Pharmacol. 2007, 59, 179-192.
23. Lu, Y.; Wang, Z.-H.; Li, T.; McNally, H.; Park, K.; Sturek, M. Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. J. Control. Release 2014, 176, 76-85.
24. Laaksonen, T.; Liu, P.; Rahikkala, A.; Peltonen, L.; Kauppinen, E.I.; Hirvonen, J.; Järvinen, K.; Raula, J. Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods. Pharm. Res. 2011,28,2403-2411.
25. Van Eerdenbrugh, B.; Vermant, J.; Martens, J.A.; Froyen, L.; Van Humbeeck, J.; Augustijns, P.; Van den Mooter, G. A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 2009, 98, 2091-2103.
26. Liu, P.; Viitala, T; Kartal-Hodzig, A.; Liang, H; Laaksonen, T; Hirvonen, J.; Peltonen, L. Interaction studies between indomethacin nanocrystals and PEO/PPO copolymer stabilizers. Pharm. Res. 2015, 32, 628-639.
27. Strachan, C.J.; Windbergs, M.; Offerhaus, H.L. Pharmaceutical applications of non-linear imaging. Int. J. Pharm. 2011, 417, 163-172.
28. Ali, H.S.M.; York, P.; Ali, A.M.A.; Blagden, N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J. Control. Release 2011, 149, 175-181.
29. Wang, M.; Rutledge, G.C.; Myerson, A.S.; Trout, B.L. Production and characterization of carbamazepine nanocrystals by electrospraying for continuous pharmaceutical manufacturing. J. Pharm. Sci. 2012, 101, 1178-1188.
30. Pireddu, R.; Sinico, C.; Ennas, G.; Marongiu, F.; Muzzalupo, R.; Lai, F.; Fadda, A.M. Novel nanosized formulations of two diclofenac acid polymorphs to improve topical bioavailability. Eur. J. Pharm Sci. 2015, 77, 208-215.
31. Verma, S.; Huey, B.D.; Burgess, D.J. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir 2009, 25, 12481-12487.
32. Wang, Y.; Zheng, Y.; Shang, L.; Wang, Q.; Zhang, D. Stability of nanosuspensions in drug delivery. J. Control. Release 2013, 172, 1126-1141.
33. Baba, K.; Pudavar, H.E.; Roy, I.; Ohulchansky, T.Y.; Chan, Y.; Pandery, R.K.; Prasad, P.N. New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug. Mol. Pharm. 2007, 4, 289-297.
34. Chen, Y.; Li, T. Cellular uptake mechanism of paclitaxel nanocrystals determined by confocal imaging and kinetic measurement. AAPS J. 2015, 17, 1126-1134.
35. Ige, P.P.; Baria, R.K.; Gattani, S.G. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf. B Biointerfaces 2013, 108, 366-373.
36. Abu-Diak, O.A.; Jones, D.S.; Andrews, G.P. An investigation into the dissolution properties of celecoxib melt extrudates: Understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol. Pharm. 2011, 8, 1362-1371.
37. Jung, J.Y.; Yoo, S.D.; Lee, S.H.; Kim, K.H.; Yoon, D.S.; Lee, K.H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm. 1999, 187, 209-218.
38. Surwase, S.A.; Itkonen, L.; Aaltonen, J.; Saville, D.; Rades, T.; Peltonen, L.; Strachan, C.J. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension. Eur. J. Pharm. Biopharm. 2015, 96, 32-43.
39. Frank, K.J.; Westedt, U.; Rosenblatt, K.M.; Hölig, P.; Rosenberg, J.; Mägerlein, M.; Fricker, G.; Brandl, M. What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion? J. Pharm. Sci. 2014, 103, 1779-1786.
40. Murdande, S.B.; Pikal, M.J.; Shanker, R.M.; Bogner, R.H. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable? J. Pharm. Sci. 2011, 100, 4349-4356.
41. Sekikawa, H.; Nakano, M.; Arita, T. Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem. Pharm. Bull. 1978, 26, 118-126.
42. Raghavan, S.L.; Trividic, A.; Davis, A.F.; Hadgraft, J. Crystallization of hydrocortisone acetate: Influence of polymers. Int. J. Pharm. 2001, 212, 213-221.
43. Yokoi, Y.; Yonemochi, E.; Terada, K. Effects of sugar ester and hydroxypropyl methylcellulose on the physicochemical stability of amorphous cefditoren pivoxil in aqueous suspension. Int. J. Pharm. 2005, 290, 91-99.
44. Warren, D.B.; Benameur, H.; Porter, C.J.H.; Pouton, C.W. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J. Drug Target. 2010, 18, 704-731.
45. Loftsson, T.; FriBriksdóttir, H.; GuBmundsdóttir, T.K. The effect of water-soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 1996, 127, 293-296.
46. Ueda, K.; Higashi, K.; Yamamoto, K.; Moribe, K. In situ molecular elucidation of drug supersaturation achieved by nano-sizing and amorphization of poorly water-soluble drug. Eur. J. Pharm. Sci. 2015, 77, 79-89.
47. Li, W.; Quan, P.; Zhang, Y.; Cheng, J.; Liu, J.; Cun, D.; Xiang, R.; Fang, L. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions. Int. J. Pharm. 2014, 460, 13-23.
48. Collnot, E.M.; Baldes, C.; Wempe, M.F.; Hyatt, J.; Navarro, L.; Edgar, K.J.; Schaefer, U.F.; Lehr, C.M. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release 2006, 111, 35-40.
49. Zhao, F.; Zhao, Y.; Liu, Y.; Chang, X.; Chen, C. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011, 7, 1322-1337.
50. Gao, L.; Liu, G.; Ma, J.; Wang, X.; Wang, F.; Wang, H.; Sun, J. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells. Colloids Surf. B Biointerfaces 2014, 117, 122-127.
51. Tang, X.J.; Fu, Y.H.; Meng, Q.H.; Li, M.; Ying, X.Y.; Han, M.; He, Q.J.; Yang, B.; Zeng, S.; Hu, Y.Z.; et al. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo. Int. J. Pharm. 2013, 456, 243-250.
52. Wang, J.; Sun, J.; Chen, Q.; Gao, Y.; Li, L.; Li, H.; Leng, D.; Wang, Y.; Sun, Y.; Jing, Y.; et al. Star-shape copolymer of lysine-linked dl-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 2012, 33, 6877-6888.
53. Varmal, M.V.; Panchagnula, R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 2005, 25, 445-453.
54. Watson, P.; Jones, A.T.; Stephens, D.J. Intracellular trafficking pathways and drug delivery: Fluorescence imaging of living and fixed cells. Adv. Drug Deliv. Rev. 2005, 57, 43-61.
55. Tenuta, T.; Monopoli, M.P.; Kim, J.; Salvati, A.; Dawson, K.A.; Sandin, P.; Lynch, I. Elution of labile fluorescent dye from nanoparticles during biological use. PLoS ONE 2011, 6, e25556.
56. Xu, P.S.; Gullotti, E.; Tong, L.; Highley, C.B.; Errabelli, D.R.; Hasan, T.; Cheng, J.X.; Kohane, D.S.; Yeo, Y. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol. Pharm. 2009, 6, 190-201.
57. Dorney, J.; Bonnier, F.; Garcia, A.; Casey, A.; Chambers, G.; Byrne, H.J. Identifying and localizing intracellular nanoparticles using Raman spectroscopy. Analyst 2012, 137, 1111-1119.
58. Krafft, C.; Dietzek, B.; Popp, J. Raman and CARS microspectroscopy of cells and tissues. Analyst 2009, 134, 1046-1057.
59. Samtani, M.N.; Vermeulen, A.; Stuyckens, K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 2009, 48, 585-600.